ENBREL

Compare ENBREL  to:
Compare
Compare

Generic Name for ENBREL

Etanercept 25mg; per vial (pwd for SC inj after reconstitution; preservative-free; diluent contains benzyl alcohol); 50mg/mL prefilled syringe (soln for SC inj; preservative free); 50mg/mL prefilled syringe SureClick autoinjector (soln for SC inj; preservative-free).

Legal Classification:

Rx

Pharmacological Class for ENBREL

Tumor necrosis factor (TNF) blocker.

Manufacturer of ENBREL

Amgen, Inc.

Indications for ENBREL

To reduce signs/symptoms, induce major clinical response, inhibit progression of structural damage, and improve physical function in patients with moderately to severely active rheumatoid arthritis; to reduce signs/symptoms, inhibit progression of structural damage of active arthritis, and improve physical function in patients with psoriatic arthritis; for both: may be used with or without methotrexate in patients who have not responded adequately to methotrexate alone. To reduce signs/symptoms of: ankylosing spondylitis, and of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients who have had an inadequate response to one or more DMARDs.

Adult dose for ENBREL

Use prefilled syringe. Inject 50mg SC once weekly into thigh, abdomen, or upper arm; rotate inj sites.

Children's dosing for ENBREL

Inject SC into thigh, abdomen, or upper arm; rotate inj sites. <2yrs: not recommended. JIA: 2–17yrs: 0.8mg/kg per week; max 50mg/week. ≥63kg: may use 50mg prefilled syringe or SureClick autoinjector.

Contraindications for ENBREL

Sepsis.

Precautions for ENBREL

Increased risk of serious or fatal infections (eg, TB, bacterial sepsis, invasive fungal). Active infections: not recommended. Chronic or recurring infections. Conditions that predispose to infection (eg, diabetes, immunosuppression). Test for and treat latent tuberculosis prior to initiating therapy. Monitor closely if new infection, or reactivation of hepatitis B virus (HBV) develop; discontinue if serious infection, sepsis, HBV reactivation, or lupus-like syndrome develops. Suspend if significant exposure to varicella occurs (consider varicella prophylaxis). Attempt to complete childhood immunizations first. CNS demyelinating disorders (eg, multiple sclerosis, myelitis, optic neuritis), seizures. Heart failure. Hematologic abnormalities (consider discontinuing if occur). Malignancies. Latex allergy (syringe). Supervise 1st dose. Elderly. Pregnancy (Cat.B). Nursing mothers: not recommended.

Interactions for ENBREL

Concurrent cyclophosphamide, anakinra, live vaccines, other TNF blockers: not recommended. Immunosuppressants increase risk of infection.

Adverse Reactions for ENBREL

Inj site reactions, infections (eg, sepsis, osteomyelitis, cellulitis, pneumonia, pyelonephritis), antibody formation, respiratory disorders, dyspepsia; worsening psoriasis; rare: CNS demyelinating disorders, pancytopenia, aplastic anemia, tuberculosis, others. Children: also varicella, headache, GI disturbances, skin ulcer, depression, personality disorder, esophagitis, gastritis.

How is ENBREL supplied?

Multi-use vials—4 (w. supplies)
Single-use prefilled syr (1mL)—4 (w. needles)
Single-use prefilled SureClick autoinjector—4 (w. needles)

Related Disease:

Ankylosing spondylitis
Arthritis~biologic response modifiers
Juvenile rheumatoid arthritis
Rheumatoid arthritis

Related Resources

Xiaflex available for Dupuytren's contracture

March 08, 2010

BioSpecifics Technologies and Auxilium Pharmaceuticals announced the availability of Xiaflex (collagenase clostridium histolyticum) for the treatment of adult Dupuytren's contracture patients with a palpable cord.

Xiaflex approved for Dupuytren's contracture

February 03, 2010

Auxilium Pharmaceuticals announced the approval of Xiaflex (collagenase clostridium histolyticum) for the treatment of adult Dupuytren's contracture patients with a palpable cord.

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

Phase 2 study of SBI-087 for treatment of rheumatoid arthritis (RA)

January 11, 2010

Trubion Pharmaceuticals announced the initiation of a Phase 2 trial of SBI-087 for the treatment of rheumatoid arthritis (RA).

Actemra approved for moderately to severely active rheumatoid arthritis

January 11, 2010

The FDA has approved Actemra (tocilizumab, from Roche) for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.